Lialda is a delayed release tablet which may help you achieve remission, controlling the symptoms of ulcerative colitis, with as few as 2 tablets taken once daily
Lialda, for the induction of remission in patients with active, mild to moderate ulcerative colitis, is the only FDA-approved, oral once-daily prescription drug. The safety and effectiveness of Lialda has been established in two 8-week trials.
Lialda (Mesalamine) (Mezavant in Canada)
